Definium Therapeutics (DFTX) Stock Forecast & Price Target
Score
Definium Therapeutics, Inc. price target
| DFTX | |
|---|---|
| Low | $52.00 |
| Average | $67.45 |
| High | $79.00 |
| Upside vs current price | +110.3% |
The average target of $67.45 is +110.3% versus the current DFTX price of $32.08.
Definium Therapeutics, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 5 |
| Buy | 14 |
| Hold | 0 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
19 analysts cover DFTX.
Definium Therapeutics, Inc. EPS and revenue estimates
The estimate table for the Definium Therapeutics, Inc. keeps 2026 EPS $-3.02, 2027 EPS $-1.99, and years with fewer than three analysts are not filled in.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-3.02 | — |
| 2027 | $-1.99 | $29.35M |
Is Definium Therapeutics, Inc. a buy or sell?
Of the 19 analysts covering Definium Therapeutics, Inc., 19 rate it a buy (5 strong buy and 14 buy), 0 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The DFTX consensus label is Buy, beside 19 buy-side ratings and 0 sell-side ratings.
The average target of $67.45 implies +110.3% versus the current price of $32.08.
the Definium Therapeutics, Inc. closes with 19 buy-side ratings and 0 on the sell side. The headcount is Buy.
Reading the Definium Therapeutics, Inc. forecast
Analysts are far apart on DFTX. The published low is $52.00, the average is $67.45, and the high is $79.00.
From today's $32.08 print, the DFTX average target is +110.3% away.
Most of the DFTX coverage agrees: 19 of 19 analysts are on the buy side, 0 are at hold, and 0 are on the sell side, and the published consensus is Buy.
Earnings estimates for DFTX are rising: 2026 $-3.02, then 2027 $-1.99.
Coverage of DFTX is broad at 19 analysts, and the average is a crowd rather than a single desk.
Definium Therapeutics, Inc. forecast questions
What is the DFTX price target?
The published range for DFTX is $52.00 to $79.00, with an average of $67.45. That average is +110.3% versus the current price of $32.08.
Is Definium Therapeutics, Inc. a buy or sell?
Of the 19 analysts covering Definium Therapeutics, Inc., 19 rate it a buy, 0 rate it a hold, and 0 rate it a sell. The consensus is Buy, which for DFTX is 19 on the buy side, 0 at hold, and 0 on the sell side.
What is the EPS estimate for Definium Therapeutics, Inc.?
Analyst EPS estimates for Definium Therapeutics, Inc.: 2026 $-3.02, 2027 $-1.99.
What is the revenue estimate for Definium Therapeutics, Inc.?
Analyst revenue estimates for Definium Therapeutics, Inc.: 2027 $29.35M.
How many analysts cover DFTX?
19 analysts cover DFTX. Their consensus on DFTX is Buy, across those 19.